, Shimpei Matsusaki1, Youichirou Baba2, Yoshiaki Isono1, Tomohiro Sase1, Hiroshi Okano1, Tomonori Saito1, Katsumi Mukai1, Tetsuya Murata2, Hiroki Taoka3
1Department of Gastroenterology, Suzuka General Hospital, Suzuka, Japan
2Department of Pathology, Suzuka General Hospital, Suzuka, Japan
3Department of Surgery, Suzuka General Hospital, Suzuka, Japan
Copyright © 2018 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
| (a) | Forceps biopsy | 80/123 |
| 65.0% | ||
| (b) | Brush cytology | 55/111 |
| 49.5% | ||
| (c) | Aspiration cytology | 36/78 |
| 46.2% | ||
| (d) | ENBD cytology | 7/32 |
| 21.9% | ||
| (e) | Combination of each procedure | 99/136 |
| 72.8% |
| Inf a (α), b (β) | Inf c (γ) | p-value | |
|---|---|---|---|
| Biliary-origin lesions (n=20) | 14/14 | 4/6 | 0.079 |
| 100% | 66.7% | ||
| Extrabiliary-origin lesions (n=19) | 7/10 | 4/9 | 0.369 |
| 70.0% | 44.4% | ||
| Total (n=39) | 21/24 | 8/15 | 0.027 |
| 87.5% | 53.3% |
| Med, int | Sci | p-value | |
|---|---|---|---|
| Biliary-origin lesions (n=20) | 13/14 | 4/6 | 0.20 |
| 92.9% | 66.7% | ||
| Extrabiliary-origin lesions (n=19) | 6/9 | 5/10 | 0.65 |
| 66.7% | 50.0% | ||
| Total (n=39) | 19/23 | 9/16 | 0.15 |
| 82.6% | 56.3% |
| Male: Female | 79: 57 |
| Age (yr) | Mean 74 (45–94) |
| Final diagnosis | |
| Pancreatic cancer | 55 |
| Extrahepatic cholangiocarcinoma | 35 |
| Gallbladder cancer | 25 |
| Intrahepatic cholangiocarcinoma | 13 |
| Ampullary carcinoma | 1 |
| Postoperative recurrences | 5 |
| Pancreatic neuroendocrine carcinoma | 1 |
| Metastatic cancer | 1 |
| (a) | Forceps biopsy | 80/123 |
| 65.0% | ||
| (b) | Brush cytology | 55/111 |
| 49.5% | ||
| (c) | Aspiration cytology | 36/78 |
| 46.2% | ||
| (d) | ENBD cytology | 7/32 |
| 21.9% | ||
| (e) | Combination of each procedure | 99/136 |
| 72.8% |
| Methods for diagnosis | |
|---|---|
| Pancreatic cancer (n=14) | EUS-FNA 4, liver biopsy 1, duodenal biopsy 2 |
| Imaging studies 7 | |
| Intrahepatic cholangiocarcinoma (n=4) | Liver biopsy 2 |
| Imaging studies 2 | |
| Gallbladder cancer (n=4) | Imaging studies 4 |
| Extrahepatic cholangiocarcinoma (n=2) | Imaging studies 2 |
| Postoperative recurrences (n=2) | Liver biopsy 1 |
| Imaging studies 1 | |
| Pancreatic neuroendocrine carcinoma (n=1) | EUS-FNA 1 |
| Ampullary carcinoma (n=1) | Duodenal biopsy 1 |
| Forceps biopsy | Brush cytology | Aspiration cytology | ENBD cytology | Total | |
|---|---|---|---|---|---|
| Pancreatic cancer (n=55) | 30/51 | 23/47 | 11/29 | 1/9 | 38/55 |
| 58.8% | 48.9% | 37.9% | 11.1% | 69.1% | |
| Extrahepatic cholangiocarcinoma (n=35) | 27/32 | 16/27 | 11/21 | 2/10 | 32/35 |
| 84.4% | 59.3% | 52.4% | 20.0% | 91.4% | |
| Gallbladder cancer (n=25) | 14/22 | 11/22 | 11/19 | 3/9 | 14/25 |
| 63.6% | 50.0% | 57.9% | 33.3% | 56.0% | |
| Intrahepatic cholangiocarcinoma (n=13) | 6/11 | 3/11 | 2/6 | 1/3 | 8/13 |
| 54.5% | 27.3% | 33.3% | 33.3% | 61.5% |
| Biliary-origin lesions (n=35) | Extrabiliary-origin lesions (n=101) | p-value | |
|---|---|---|---|
| Forceps biopsy | 27/32 | 53/91 | 0.00923 |
| 84.4% | 58.2% | ||
| Brush cytology | 16/27 | 39/84 | 0.28 |
| 59.3% | 46.4% | ||
| Aspiration cytology | 11/21 | 25/57 | 0.61 |
| 52.4% | 43.9% | ||
| ENBD cytology | 2/10 | 5/22 | 1.00 |
| 20.0% | 22.7% | ||
| Total | 32/35 | 67/101 | 0.00378 |
| 91.4% | 66.3% |
| Inadequate material | Insufficient material | Normal bile duct epithelium | Inflammatory atypia/Reactive change | |
|---|---|---|---|---|
| Forceps biopsy | 4/43 | 5/43 | 33/43 | 3/43 |
| 9.3% | 11.6% | 76.7% | 7.0% | |
| Brush cytology | 3/56 | 4/56 | 54/56 | 0/56 |
| 5.4% | 7.1% | 96.4% | 0% | |
| Brush cytology | 4/42 | 1/42 | 38/42 | 0/42 |
| 9.5% | 2.4% | 90.5% | 0% | |
| Aspiration cytology | 1/25 | 1/25 | 23/25 | 2/25 |
| 4.0% | 4.0% | 92.0% | 8.0% |
| Inf a (α), b (β) | Inf c (γ) | p-value | |
|---|---|---|---|
| Biliary-origin lesions (n=20) | 14/14 | 4/6 | 0.079 |
| 100% | 66.7% | ||
| Extrabiliary-origin lesions (n=19) | 7/10 | 4/9 | 0.369 |
| 70.0% | 44.4% | ||
| Total (n=39) | 21/24 | 8/15 | 0.027 |
| 87.5% | 53.3% |
| Med, int | Sci | p-value | |
|---|---|---|---|
| Biliary-origin lesions (n=20) | 13/14 | 4/6 | 0.20 |
| 92.9% | 66.7% | ||
| Extrabiliary-origin lesions (n=19) | 6/9 | 5/10 | 0.65 |
| 66.7% | 50.0% | ||
| Total (n=39) | 19/23 | 9/16 | 0.15 |
| 82.6% | 56.3% |
ENBD, endoscopic nasobiliary drainage.
EUS-FNA, endoscopic ultrasound-guided fine needle aspiration.
ENBD, endoscopic nasobiliary drainage.
ENBD, endoscopic nasobiliary drainage.
